Apply Now

COPD Research Study

Researchers at the Lundquist Institute are testing an investigational drug for treating airway inflammation in patients with COPD (Chronic Obstructive Pulmonary Disease).

Apply Now

Fast Facts

Former Smoker Diagnosed with COPD (Chronic Obstructive Pulmonary Disease)

Ages 40-70

Have Experienced a Worsening or Flare-up of Symptoms Related to COPD within the past 5 Years

Compensation Provided

Conducted in Los Angeles County, CA

Study Background

Researchers at the Lundquist Institute are testing itepekimab as a treatment for symptoms of COPD (Chronic Obstructive Pulmonary Disease).

In this study, we will investigate the impact of itepekimab, an investigational drug, on airway inflammation in patients with COPD who continue to have symptoms on current treatment. In addition to its effects, we want to understand the mechanism by which itepekimab acts on airway inflammation. In the long-term, understanding how medications like itepekimab work could help us develop more effective treatments for symptoms of COPD. 
Participants in our study will complete a total of 10 visits, of which 7 will be in-person and 3 will be over the phone. They will provide nasal and blood samples, as well as undergo two bronchoscopies.

Study Background

Researchers at the Lundquist Institute are testing itepekimab as a treatment for symptoms of COPD (Chronic Obstructive Pulmonary Disease).

In this study, we will investigate the impact of itepekimab, an investigational drug, on airway inflammation in patients with COPD who continue to have symptoms on current treatment. In addition to its effects, we want to understand the mechanism by which itepekimab acts on airway inflammation. In the long-term, understanding how medications like itepekimab work could help us develop more effective treatments for symptoms of COPD. 

Participants in our study will complete a total of 10 visits, of which 7 will be in-person and 3 will be over the phone. They will provide nasal and blood samples, as well as undergo two bronchoscopies.
Apply Now

Additional Information

Through this research, we aim to understand how itepekimab, an investigational drug, impacts airway inflammation in patients with COPD and the mechanism by which it works. We hope that our results can help us determine the efficacy of itepekimab as a treatment for COPD symptoms as well identify ways to develop improved COPD treatments.

You may qualify for this study if you meet the following criteria.

Inclusion Criteria:

  • Ages 40-70
  • Diagnosed with COPD (Chronic Obstructive Pulmonary Disease)
  • Former smoker
  • Have experienced a worsening or flare-up of symptoms related to COPD within the past 5 years

Participants in our study will attend a total of 10 visits: 7 in-person and 3 over the phone. At some of the in-person visits, we will collect nasal and blood samples, take vital signs, and perform an EKG. Participants will also undergo 2 bronchoscopies during the study.

Participants will receive between $75 and $100 per visit, for a total of up to $575 over the course of the study.

There is no cost for you to participate in our research study.

Terms of Service

Privacy Policy

Terms of Service

Privacy Policy

Tagged